Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

LipoScience Gives Its Shareholders Chest Pains
Stephen Simpson • BDX, RHHBY.OB, DHR • Tue, May 14, 17:03 ET
Chembio: A Potentially Undervalued Diagnostics Biotech
Zhen Lu • CEMI • Thu, May 2, 13:48 ET
Venaxis Poised For Run-Up Into Pivotal Study Results
Mike Havrilla • APPY • Sun, Apr 28, 17:31 ET
The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy
PropThink • ALNY, TKMR • Tue, Apr 23, 11:53 ET
There Is A Lot To Like About Celldex Therapeutics
C.R. Jackson • AMGN, BMY, MRK • Wed, Apr 17, 06:11 ET
OncoGenex: A Cancer Biotech Worth Betting On
BlackbirdAnalytics • OGXI • Fri, Apr 12, 13:45 ET
Tekmira's TKM-PLK1 Is Promising For Solid Tumors
Grant Zeng • TKMR • Wed, Apr 10, 08:38 ET
Nymox Pharma: Developing A Potential Long-Term Treatment For BPH
Mike Havrilla • NYMX • Wed, Apr 3, 16:43 ET
Promising RNA Company Tekmira Ready To Release Data At AACR 2013
Brian L. Wilson • TKMR • Tue, Apr 2, 15:59 ET
Immunomedics' Strengthened Balance Sheet Supports A Compelling Trade Ahead Of Presentations
PropThink • IMMU • Tue, Apr 2, 13:12 ET
OncoGenex's Second Cancer Drug Gaining Investor Attention
Len Zehr • OGXI • Tue, Mar 26, 17:51 ET
Synta's Slump On Shelf Registration Provides Entry Point Ahead Of ASCO
PropThink • SNTA • Mon, Mar 25, 11:26 ET
Tekmira: An Undervalued Pioneer In The Field Of RNAi Therapeutics
Grant Zeng • TKMR • Thu, Mar 21, 10:49 ET
What's Going On With Celldex?
Brian L. Wilson • CLDX • Thu, Mar 14, 03:04 ET
OncoGenex: SYNERGY Trial Is The Major Catalyst In Sight
Biomed Group • OGXI • Wed, Mar 13, 07:58 ET
Chembio Caps 2012 With Another Revenue Record
Brian Marckx • CEMI • Tue, Mar 12, 13:10 ET
What Is Driving Celldex Therapeutics' Share Value?
InvestorR • CLDX • Mon, Mar 11, 11:15 ET
Immunomedics Has A Cheap, Deep And Recently Capitalized Pipeline
PropThink • CELG, GSK, IMMU • Fri, Mar 1, 12:45 ET
Synta Pharmaceuticals' Subgroup Selection Strategy Is A Set-Up For Success
PropThink • SNTA • Thu, Feb 28, 10:01 ET
Venaxis: Appendicitis Screening Just Became Cheaper
Doolan Wesley • ABT, JNJ, MRK • Wed, Feb 27, 16:05 ET
Celldex Therapeutics: Breakthrough Drugs At A Bargain Price
Jonathan Faison • CLDX • Tue, Feb 26, 13:23 ET
LipoScience - A Small Company Targeting A Large Market
Stephen Simpson • ALR, QGEN, LH • Tue, Feb 26, 09:13 ET
LipoScience - Disappointing Offering In A Strong Public Offering Season
The Value Investor • LPDX • Tue, Feb 19, 04:08 ET
Anything Can Happen This Year For Celldex
Equity Options Guru • SGEN, CLDX • Mon, Feb 18, 09:11 ET
Is Celldex Worth The Risk In 2013?
Teresa Dawn • CLDX • Thu, Feb 7, 16:33 ET
Venaxis' 'APPY1' Set For Great Year
James Stephens • APPY • Thu, Feb 7, 16:02 ET
With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
M. E. Garza • ALNY, TKMR • Fri, Feb 1, 05:53 ET
IPO Preview: LipoScience
IPOdesktop • LPDX • Thu, Jan 24, 20:59 ET
Synta: Share Price Not Reflecting Ganetespib Value Proposition
Poonam A. Arora • ARRY, ASTX, AZN • Tue, Jan 15, 12:09 ET
Venaxis Still Faces Challenges For Its APPY1 Test
Brian L. Wilson • APPY • Wed, Jan 9, 11:39 ET
Chembio Diagnostics: Growing Sales And Profits With Near-Term FDA Catalyst
Mike Havrilla • ALR, OSUR, CEMI • Thu, Dec 20, 2012, 10:12 ET
Synta Pharma: Poised For A Breakout With 4 Near-Term Catalysts
Scott Matusow • ARIA, BMY, GSK • Thu, Dec 13, 2012, 12:26 ET
Abaxis: Buy The Market's Oversight
QuandaryFX • ABAX • Tue, Nov 27, 2012, 18:48 ET
Why I Think Rosetta Genomics Will See $20 In 1-2 Years
Carl Cachia • ROSG • Wed, Nov 21, 2012, 13:22 ET
Tekmira Could Offer Stockholders Huge Rewards
C.R. Jackson • BMY, MRK, ALNY • Thu, Nov 15, 2012, 11:17 ET
Palatin Investors Prepared For The Long Haul With Another FSD Drug
Brian L. Wilson • BPAX, PTN • Wed, Nov 14, 2012, 11:46 ET
A Balanced, Scientific View Of AspenBio Biopharma (Soon To Be Venaxis)
amirstep • APPY • Wed, Oct 24, 2012, 15:27 ET
Buy Trinity Biotech: A Safe Biotech Stock Poised For Growth
Qineqt • TMO, TRIB • Wed, Oct 3, 2012, 17:22 ET
2 Reasons To Consider Abaxis In The Wake Of A Recent Downgrade
Matt Schilling • ABAX • Tue, Sep 25, 2012, 11:07 ET
Why Rosetta Genomics Is Deeply Undervalued
Joseph Morsi • ROSG • Thu, Sep 6, 2012, 17:43 ET
Catching Up With Celldex Therapeutics
Stephen Simpson • PFE, BMY, AMGN • Mon, Aug 13, 2012, 13:55 ET
Chembio's Q2: Continued Strong Revenue Growth, OTC Program Moving Forward
Brian Marckx • OSUR, CEMI • Sun, Aug 12, 2012, 10:15 ET
Substantial Potential In Celldex Therapeutics
Chimera Research Group • CLDX • Thu, Aug 9, 2012, 15:59 ET
Earnings Preview: Celldex Therapeutics Reports August 10
Vytautas Drumelis • AMGN, DNDN, PFE • Tue, Aug 7, 2012, 19:38 ET
6 Reasons To Buy AspenBio Pharma
Markus Aarnio • APPY • Thu, Jul 26, 2012, 04:44 ET
Nymox Advances Its Mystery Prostate Weapon Into Phase III
Praveen Jayarajan • NYMX • Fri, Jul 13, 2012, 11:44 ET
Abaxis: Aggressive Growth Stock With Bright Prospects Ahead
Zacks Investment Research • ABAX • Wed, Jul 11, 2012, 04:34 ET
Synta - The Signal Looks Real
Ohad Hammer • ARRY, SNTA, AZN • Tue, Jul 10, 2012, 02:18 ET
3 Reasons To Buy Synta Pharmaceuticals
Markus Aarnio • SNTA • Mon, Jul 2, 2012, 14:31 ET
AMAG Receives EU Approval For Iron Drug With Phase III Results Expected Soon
Mike Havrilla • TKPYY.PK, AMAG • Fri, Jun 22, 2012, 14:38 ET

First Page
Previous Page
1 - 50 of 157
Next Page
Last Page